Back

Notification report


Full notification file


General information

Notification Number
B/DE/16/PEI2623

Member State to which the notification was sent
Germany

Date of acknowledgement from the Member State Competent Authority
21/12/2015

Title of the Project
A Phase 1b/3, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With Pembrolizumab for Treatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (20130232)

Proposed period of release:
01/01/2016 to 31/12/2022

Name of the Institute(s) or Company(ies)
Amgen Limited, UK, On behalf of Amgen Inc. (study sponsor);


3. Is the same GMO release planned elsewhere in the Community?
Yes:
Belgium; Germany; Spain; France; Greece; Netherlands; Sweden; Poland;

Has the same GMO been notified elsewhere by the same notifier?
Yes

If yes, notification number(s):
B/ES/14/05; B/ES/14/06; B/ES/14/08; B/ES/15/04; B/FR/15/GT01; B/FR/15/GT06; B/FR/15/GT07; B/HU/14/01; B/SE/14/EU-2014-000185-22;

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
Identity of the GMO (genus and species)
Genus: Simplexvirus
Species: Talimogene laherparepvec is a recombinant of a wild type Herpes simplex virus 1 (HSV-1) strain JS1, with genes ICP34.5 and ICP47 deleted and hGM-CSF inserted


Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
HSV-1SimplexvirusHSV-1-JS1 (ECACC Accession Number 01010209)

European Commission administrative information

Consent given by the Member State Competent Authority:
Yes
06/07/2016 00:00:00
Remarks: